Organogenesis (NASDAQ:ORGO) reported record fourth-quarter 2025 results that surpassed the high end of the revenue range the company had outlined on its third-quarter call, driven primarily by ...

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacturing, and sale of products ...

Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercialization of product solutions for the Advanced Wound Care and ...

Organogenesis shares have dropped ~42% since my last 'Hold' rating, reflecting ongoing challenges in its core business. Q1 2025 earnings disappointed, with the dominant Advanced Wound Care segment ...

To put it charitably, the market wasn't impressed with the company's recent performance. They traded out of the stock following the publication of quarterly and annual results. The wound care ...

Seeking Alpha's quant ratings system provides a valuable tool for analysis of thousands of stocks. Underlying metrics for momentum and revisions undercut Organogenesis' strong Quant valuation and ...

Integra LifeSciences said on Tuesday that it was doing a voluntary recall of products, which could be worth as much as $60 million if the recall lasts all of 2023. Integra said it was doing a global ...

Robust 218-patient RCT demonstrates statistically superior frequency of wound closure at 12 weeks compared to standard of care (p=.04) Organogenesis believes published study satisfies requirements for ...

The latest price target for Organogenesis Holdings (NASDAQ:ORGO) was reported by Cantor Fitzgerald on August 8, 2025. The analyst firm set a price target for $9.00 expecting ORGO to rise to within 12 ...

PROVIDENCE — Rhode Island Commerce Corporation has granted Organogenesis, a Massachusetts biotech firm, more than $13 million in tax incentives, to support the company’s opening of a new manufacturing ...

NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Organogenesis Holdings, Inc. (NASDAQ: ORGO) on ...

CANTON, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company, today announced it has received U.S. Food and Drug Administration (FDA) 510k Clearance for ...